Maven's asset-light marketplace model contracts with independent providers rather than employing them directly, enabling rapid geographic expansion without capital investment and lower regulatory burden than direct healthcare provision. The company's value proposition centers on reducing healthcare costs while improving outcomes—members see up to 27% fewer NICU stays and 15% fewer C-sections, while Maven saves employers an average of $9,600 per birth. More than 2,000 employers and health plans trust Maven's end-to-end platform.
Cyborg Score Rationale
Maven is valued at $1.7 billion with estimated $268M in annual recurring revenue for 2024, representing a 6.9x forward revenue multiple. The company demonstrates strong product-market fit with rapid growth across multiple programs—Menopause & Midlife achieved 300% year-over-year growth with 550+ clients, and Maternity & Newborn Care experienced 400% client growth in the past year. Strategic positioning in a $4 trillion industry with proven outcome economics and deep enterprise relationships supports sustainable scaling.
Top Insights
Platform generates revenue through dual model: $20-40K annual platform fees plus per-member fees ranging from $700/year for fertility support to $950/year for maternity care, plus Maven Wallet benefits administration at $800/enrollee/year
Maternity & Newborn Care program offered by >90% of Maven clients achieved 400% growth in past year, with <600 clients now offering Menopause & Midlife services (300% YoY growth)
Since 2022, Maven has tripled Medicaid market presence and is moving deeper into value-based risk contracts
Consumer platform launched in March 2026 offering direct-to-consumer GLP-1 care, hormone care, and virtual specialty services across 30+ specialties
Named Competitors
Progyny — Public fertility and family-building benefits platform
Carrot Fertility — Fertility-benefits specialist with global employer coverage
Kindbody — Clinic-based fertility and family-building provider
Ovia Health — Comprehensive digital women's and family health platform for family-building, maternity, and menopause benefits
Recent Developments
(May 2026) Maven research finds nearly half of providers lack sufficient time to support patients after prescribing GLP-1s or hormone therapy
(March 2026) Launched Maven Intelligence integrating agentic AI with longitudinal clinical data to power personalized care across fertility, maternity, parenting, and menopause
(February 2026) Partnered with Color Health to expand virtual oncofertility services
(October 2024) Closed $125 million Series F funding round at $1.7 billion valuation led by StepStone Group
Open the full interactive Maven Clinic report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.